Global Aminoglycosides Market Analysis 2019-2024: Forecast by Product, Route of Administration, Application and Geography – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Aminoglycosides Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.

The global aminoglycosides market size is expected to witness a growth of over 4.3% CAGR over the forecast period, owing to the increasing burden of animal disease outbreaks leading to high utilization of antibiotics.

Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and are frequently used as a second line of defense against basic infection resistant to basic antibacterials.

Additionally, reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to affect the market growth negatively.

Key Market Trends

Gentamicin Accounted for the Largest Share in the Global Market

Neomycin, streptomycin, gentamicin, kanamycin, tobramycin, amikacin, and others are included in the product categorization of aminoglycosides. Streptomycin is a first level antibacterial used for the treatment of tuberculosis. Aminoglycosides used in the treatment of MDR-TB include kanamycin capreomycin and amikacin.

Gentamicin is the agent of choice for major bacterial infections amongst others. Tobramycin has been found to be slightly more effective against Pseudomonas aeruginosa infections. Amikacin and gentamicin find maximum usage in veterinary medicine. Gentamicin is indicated in perinatal complications, sepsis, acute/chronic renal disease, labor or neonatal complications, diabetes, and UTI/pyelonephritis.

Gentamicin forms the first line of treatment for many disorders in both developing and developed markets. Its usage is particularly high in developing regions where older gentamicin is a cost-effective and efficacious drug for many infectious diseases. Thus, its demand is consistently growing for a range of bacterial infection related diseases, with several players using it in combinations.

North America Dominates the Global Aminoglycoside Market

Geographically the aminoglycoside market is classified into North America, South America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global aminoglycoside market in terms of value due to increasing incidence of bacterial infections.

The growing demand for early-phase diagnosis and treatment of infectious diseases is expected to drive the growth of the aminoglycoside market in North America. According to the 2017 data published by the Centres for Disease Control & Prevention (CDC), in 2016 the total approximate number of visits in the US, to physician offices for infectious diseases was 16.8 million. The increasing incidence rate and high patient-visit volume for infectious diseases is the primary driver for North America’s largest share in Aminoglycoside market

Europe is the second largest market for aminoglycoside in terms of value as there are favorable government policies regarding health care infrastructure and awareness of the population.

Competitive Landscape

The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Incurable Status of the Disease

4.2.2 Global increase in Aging Population

4.2.3 Increasing Prevalence of Brain Disorders

4.3 Market Restraints

4.3.1 Adverse and Toxic Reactions Associated with Aminoglycosides

4.4 Porter’s Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry


5.1 Product

5.1.1 Neomycin

5.1.2 Tobramycin

5.1.3 Gentamicin

5.1.4 Amikacin

5.1.5 Paromomycin

5.1.6 Streptomycin

5.1.7 Kanamycin

5.1.8 Other Aminoglycosides

5.2 Route of Administration

5.2.1 Parenteral

5.2.2 Intra-mammary

5.2.3 Topical

5.2.4 Oral

5.3 Application

5.3.1 Veterinary

5.3.2 Skin Infection

5.3.3 Respiratory Diseases

5.3.4 UTI & Pelvic Diseases

5.3.5 Other Diseases

5.4 Geography

5.4.1 North America US Canada Mexico

5.4.2 Europe Germany UK France Italy Spain Rest of Europe

5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa

5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Alfasan International B.V.

6.1.2 Hangzhou Uniwise International Co. Ltd.

6.1.3 HuvePharma

6.1.4 Jiangxi Bolai Pharmacy Co. Ltd.

6.1.5 Kremoint Pharma Pvt. Ltd.

6.1.6 Medico Remedies Pvt. Ltd.

6.1.7 Medson Pharmaceuticals

6.1.8 Vega Pharma Ltd.

6.1.9 Xian Wison Biological Technology Co. Ltd.

6.1.10 Yi Chang Veterinary Medicine Factory


For more information about this report visit https://www.researchandmarkets.com/r/o60c37



Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Infectious Disease Testing

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.